For this reason, they added oncolytic virotherapy to BRAF inhibition in TC to obtain a more favorable tumor immune microenvironment, as well as increase the inflammatory status of cancers and ameliorate BRAF inhibitor therapy. Here, BRAF is linked to cancer.